Dvorákovo nábrežie 10
11 articles with AXON Neuroscience
AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases, is developing a promising vaccine candidate against COVID-19. Axon has over 20 years' experience in development of safe and immunogenic peptide vaccines. Its well-established
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
AADvac1 has a disease-modifying effect on Alzheimer's Disease, evidenced by a combination of several biomarkers and clinical outcomes, most pronounced among younger patients;
During a presentation at the AAT-AD/PD 2020 conference, Axon said AADvac1 showed a disease-modifying effect on Alzheimer's disease.
AXON Neuroscience SE has announced the results of the Phase II trial for AADvac1, its first-in-class vaccine to slow down the progression of Alzheimer's Disease.
AXON NEUROSCIENCE SE announces the appointment of Michal Fresser as Chief Executive Officer of Axon Group.